to grow double-digits in prioritized businesses through key growth vectors 5. All Rights Reserved 2024 28 Solutions provider of customized color and functionality to enhance and improve polymers Color, Additives and Inks – an overview 34% 37%21% 8% 2023 sales by region US, Canada Asia Europe, Middle East, Africa Latin America $2.0B • Differentiate and enhanced aesthetic appeal of our customers’ products • Enable sustainability through our solutions • Safeguard and preserve packaged contents • Extend product shelf life #1 KEY E N D MARKETS PACKAGING CONSUMER HEALTHCARE BUILDING & CONSTRUCTION INDUSTRIAL TRANSPORTATION Copyright © . Amplify innovation to grow double-digits in prioritized businesses through key growth vectors 5.

Schematic representation of creep mechanism; chain alignment and void formation in response to applied stress. 3© 2021 Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 There are several key factors which can influence the timeline to ESC failure: 1. Table 1 shows a summary of the disinfectants and key features, such as the EPA registration number and relevant ingredients.

PolyOne Corporation Page 4 PolyOne Commodity to Specialty Transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2014 2015 and beyond • Steve Newlin appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • 18 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth PolyOne Corporation Page 5 Building & Construction 13% Industrial 12% Transportation 18% Wire & Cable 9% Packaging 16% Consumer 10% HealthCare 11% Appliance 6% Electronics & Electrical 5% 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion PolyOne At A Glance United States 67% Europe 14% Canada 7% Asia 6% Latin America 6% Specialty 54% PP&S 18% Distribution 28% $13 $31 $46 $46 $92 $96 $122 $195 $0 $50 $100 $150 $200 2006 2007 2008 2009 2010 2011 2012 2013 Specialty Operating Income PolyOne Corporation Page 6 Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 64% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2013 Q1 2014 2015 % o f O p e ra ti n g I n c o m e * JV's Performance Products & Solutions Distribution Specialty 65-75% Specialty OI $5M $46M $87M $195M $60M Target Mix Shift Highlights Specialty Transformation 2015 Target PolyOne Corporation Page 7 Confirmation of Our Strategy The World’s Premier Provider of Specialized Polymer Materials, Services and Solutions Specialization Globalization Operational Excellence Commercial Excellence PolyOne Corporation Page 8 -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% 450.00% 550.00% POL S&P 500 Strategy and Execution Drive Results $0.12 $0.27 $0.21 $0.13 $0.68 $0.82 $1.00 $1.31 '06 '07 '08 '09 '10 '11 '12 '13 ‘06-‘13 EPS CAGR = 41% EPS Share Price vs. S&P 500 All time high of $42.47 June 6th, 2014 PolyOne Corporation Page 9 2006 Q1 2014 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 13.8% 12 – 16% Global Specialty Engineered Materials 1.1% 11.6% 12 – 16% Designed Structures & Solutions -- 6.5% 8 – 10% Performance Products & Solutions 5.5% 7.7% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 64% 65 – 75% 3) ROIC* 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 42% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period PolyOne Corporation Page 10 Bridge to $2.50 Adjusted EPS by 2015 2015 EPS: $2.50 2013 EPS: $1.31 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental Share Buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid Single Digit Revenue CAGR PolyOne Corporation Page 11 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 Specialty Vitality Index Target ≥ 35% PolyOne Corporation Page 12 Healthcare Consumer Packaging and Additive Technology Transportation Unique and Innovative Solutions https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG PolyOne Corporation Page 13 Megatrends Aligned with Key End Markets Decreasing Dependence on Fossil Fuels Protecting the Environment Improving Health and Wellness Megatrend End Markets Globalizing and Localizing Health & Wellness Transportation Packaging Consumer PolyOne Corporation Page 14 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of March 31, 2014 Debt Maturities & Pension Funding – 3/31/14 Net Debt / EBITDA* = 1.9x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 3/31/2014 PolyOne Corporation Page 15 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return $0.16 $0.20 $0.24 $0.32 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend  Expanding our sales, marketing, and technical capabilities  Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin  Synergy opportunities  Adjacent material solutions  Repurchased 1.4 million shares in Q1 2014  Repurchased 6.4 million shares since April 2013  13.6 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends  Investing in operational and LSS initiatives (including synergy capture)  Manufacturing alignment PolyOne Corporation Page 16 Formula for Success Innovation Market Beating Performance Excellence in Execution PolyOne Corporation Page 17 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne?

MEDICAL DEVICE DISINFECTION—HOW TO PREVENT CRACKING AND CRAZING Understanding polymer performance is key to minimizing disinfectant-related failures DISINFECTANT-RELATED DAMAGE ON POLYMER HOUSINGS Strong chemicals used to reduce hospital- acquired infections can damage equipment and result in material failures, such as: • Stress cracking • Crazing • Discoloration CHEMICAL RESISTANCE REQUIREMENTS VARY BY ENVIRONMENT • Patient/exam rooms • Operating and radiology rooms • Reception areas • Home (patient equipment & devices) Healthcare devices must perform flawlessly in a myriad of challenging environments and engineers must be certain their devices can withstand increasingly potent disinfectants, which have begun to outstrip the performance of traditional polymers.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Available as additive concentrates, ready-to-use additive formulations or ready-to-use additive/ colorant formulations for different polymers REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request; exceptions may occur Healthcare use limitations apply—see below.

KEY CHARACTERISTICS Avient CRTM panels offer significant benefits to customers, including: • Superior strength to weight ratio • Unlimited length capability; widths up to 108" • Thermal insulation • Ultra-low thermal conductivity • Customized density, thickness, weight and color • Vibration damping and acoustic insulation • Chemical and corrosion resistance • Consistent cross-sections and quality PRODUCT BULLETIN Other thicknesses/architectures are available.

GLASFORMS™ ELECTRICAL COMPONENTS Composite Materials for Power Transmission and Distribution Products APPLICATION & PRODUCT SELECTION GUIDE KEY CHARACTERISTICS Extend the service life of electrical transmission and distribution products with Glasforms composite technologies.

This technology offers manufacturing efficiencies versus other crosslinking methods: • Reduction in logistics management: No secondary steps after manufacturing; no need for E-beam radiation for effective crosslinking • Rapid ambient curing: Typically in less than 15 days depending on the climatic condition, wall thickness and catalyst level • No additional capital investment: The material can be processed on a conventional extrusion line • Easy handling: ECCOH XL 8001 is used with 2.5–5% of catalyst masterbatch • No pre-drying: No need to pre-dry the material if it is stored correctly PRODUCT BULLETIN KEY CHARACTERISTICS Avient’s ECCOH line of highly flame retardant, non-halogenated materials limits the emission of corrosive gases when burning.

KEY PERFORMANCE PROPERTIES1 PHYSICAL NOMINAL VALUE UNIT TEST METHOD Density/Specific Gravity 1.00 ASTM D792 Melt Mass-Flow Rate (MFR) (230°C/2.16kg) 20 g/10 min ASTM D1238 MECHANICAL Tensile Strength 15.0 MPa ASTM D638 Flexural Modulus 1400 MPa ASTM D790 Flexural Strength 35.0 MPa ASTM D790 IMPACT Notched Izod Impact (Injection Molded) 150 J/m ASTM D256 ELECTRICAL Surface Resistivity < 100000 ohms/sq ASTM D257 PROCESSING INFORMATION INJECTION NOMINAL VALUE UNIT Drying Temperature 80 to 90 °C Drying Time 4.0 to 6.0 hr Processing (Melt) Temperature 220 to 250 °C Mold Temperature 30 to 80 °C Trilliant™ HC Electrically Conductive Formulations for Precision Performance Pipette Tips A critical design consideration for pipette tips is the accurate measurement of finite amounts of liquid.

KEY CHARACTERISTICS ECCOH 5924FORMULATION ECCOH 5981 FORMULATION ECCOH 5983 UV FORMULATION Material Standards BS7655-6, 1 (LTS1–4), BS6724, IEC 60502 BS7655-6, 1 (LTS3) BS7655-6, 1 (LTS1–4) Tear Strength at 23°C 7.7 N/mm 10 N/mm 11 N/mm Tear Strength at 65°C 2.3 N/mm 5 N/mm 6.5 N/mm Hot Pressure Test (6h at 90°C) 39% –